Abstract
Introduction: Oncotype DX Breast Recurrence Score (RS) has proven to be useful in predicting the risk of recurrence and the potential benefit of chemotherapy in hormone-receptor positive, HER-2 negative early-stage breast cancer patients. The aim of this study (part of service evaluation) was to explore the role of Oncotype DX recurrence scores in the treatment of older versus younger women, treated within the Hywel Dda Health-Board between 2010 to 2018.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
